Gegenanzeigen · Pegasys
Pegasys 90 micrograms solution for injection in pre-filled syringe Pegasys 135 micrograms solution for injection in pre-filled syringe Pegasys 180 micrograms solution for injection in pre-filled syringe · Abschnitt 4.3 · PDF-Seite 11
HOS-109794 · Präparat HOS-093265
• Hypersensitivity to the active substance, to alfa interferons, or to any of the excipients listed in section 6.1 • History or presence of autoimmune diseases • Pre-existing thyroid disease unless it can be controlled with conventional treatment • Severe hepatic dysfunction or decompensated cirrhosis of the liver • A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months (see section 4.4) • HIV-HCV patients with cirrhosis and a Child-Pugh score ≥ 6, except if only due to indirect hyperbilirubinemia caused by medicinal products such as atazanavir and indinavir • Combination with telbivudine (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) telbivudine (HOS-088129)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage 1f98180aff26f1ffe55dad933e2b403ec59d2525331f1335f064e3709361733f · Zeichen 0–772 im Abschnitt